Beaten Down COVID-19 Vaccine Partner Stock Catalent Finalizes Deal With Activist Investor, Reports Mixed Q4 Earnings
Portfolio Pulse from Vandana Singh
Catalent Inc has finalized a deal with Elliott Investment Management, appointing four new independent directors to its board and establishing a Strategic and Operational Review Committee. The company reported Q4 adjusted EPS of $0.09, missing the consensus of $0.10, with sales of $1.07 billion, down 17% Y/Y. Catalent forecasts FY24 sales of $4.30 billion-$4.50 billion. The company has faced acquisition interest from multiple entities and has been navigating through multiple challenges recently.
August 29, 2023 | 12:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Danaher Corporation was rumored to be considering an acquisition of Catalent.
The rumor of Danaher considering an acquisition of Catalent could potentially increase the stock price of Danaher if the acquisition is perceived as beneficial.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
POSITIVE IMPACT
Catalent is producing Novo Nordisk's weight-loss drug, Wegovy, at their Brussels factory.
Catalent's production of Novo Nordisk's weight-loss drug could potentially increase the stock price of Novo Nordisk if the drug is successful.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Catalent collaborated with AstraZeneca to facilitate COVID-19 vaccine distribution.
Catalent's collaboration with AstraZeneca for COVID-19 vaccine distribution could potentially impact the stock price of AstraZeneca, but the impact is uncertain.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Catalent finalizes deal with Elliott Investment Management and reports mixed Q4 earnings.
The deal with Elliott Investment Management and the appointment of new directors could bring positive changes to the company. However, the missed Q4 EPS consensus and the challenges the company is facing could negatively impact the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Catalent collaborated with Johnson & Johnson to facilitate COVID-19 vaccine distribution.
Catalent's collaboration with Johnson & Johnson for COVID-19 vaccine distribution could potentially impact the stock price of Johnson & Johnson, but the impact is uncertain.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50
NEUTRAL IMPACT
Catalent collaborated with Moderna to facilitate COVID-19 vaccine distribution.
Catalent's collaboration with Moderna for COVID-19 vaccine distribution could potentially impact the stock price of Moderna, but the impact is uncertain.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50